These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

541 related items for PubMed ID: 24083402

  • 21. Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes.
    Imran F, Phatak P.
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):297-304. PubMed ID: 19670988
    [Abstract] [Full Text] [Related]

  • 22. Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.
    Alavi S, Ebadi M, Ghazizadeh F, Arzanian MT, Shamsian B, Abdollah Gorji F.
    Pediatr Hematol Oncol; 2014 Feb; 31(1):76-86. PubMed ID: 24383712
    [Abstract] [Full Text] [Related]

  • 23. Deferasirox.
    Stumpf JL.
    Am J Health Syst Pharm; 2007 Mar 15; 64(6):606-16. PubMed ID: 17353569
    [Abstract] [Full Text] [Related]

  • 24. One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation.
    Inati A, Kahale M, Sbeiti N, Cappellini MD, Taher AT, Koussa S, Nasr TA, Musallam KM, Abbas HA, Porter JB.
    Pediatr Blood Cancer; 2017 Jan 15; 64(1):188-196. PubMed ID: 27576370
    [Abstract] [Full Text] [Related]

  • 25. Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia.
    Lee SE, Yahng SA, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Kim HJ, Cho SG, Kim DW, Min WS, Park CW, Lee JW.
    Acta Haematol; 2013 Jan 15; 129(2):72-7. PubMed ID: 23154600
    [Abstract] [Full Text] [Related]

  • 26. Twice daily deferasirox significantly improves clinical efficacy in transfusion dependent thalassaemias who were inadequate responders to standard once daily dose.
    Pongtanakul B, Viprakasit V.
    Blood Cells Mol Dis; 2013 Aug 15; 51(2):96-7. PubMed ID: 23566753
    [No Abstract] [Full Text] [Related]

  • 27. Deferasirox effectively decreases iron burden in patients with double heterozygous HbS/β-thalassemia.
    Voskaridou E, Plata E, Douskou M, Sioni A, Mpoutou E, Christoulas D, Dimopoulou M, Terpos E.
    Ann Hematol; 2011 Jan 15; 90(1):11-5. PubMed ID: 20661572
    [Abstract] [Full Text] [Related]

  • 28. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention.
    Kwiatkowski JL, Cohen AR, Garro J, Alvarez O, Nagasubramanian R, Sarnaik S, Thompson A, Woods GM, Schultz W, Mortier N, Lane P, Mueller B, Yovetich N, Ware RE, SWiTCH Study Investigators.
    Am J Hematol; 2012 Feb 15; 87(2):221-3. PubMed ID: 22120913
    [Abstract] [Full Text] [Related]

  • 29. Increased serum hepcidin levels during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndrome.
    Ghoti H, Fibach E, Westerman M, Gordana O, Ganz T, Rachmilewitz EA.
    Br J Haematol; 2011 Apr 15; 153(1):118-20. PubMed ID: 21332711
    [Abstract] [Full Text] [Related]

  • 30. Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients.
    Keshtkaran A, Javanbakht M, Salavati S, Mashayekhi A, Karimi M, Nuri B.
    Transfusion; 2013 Aug 15; 53(8):1722-9. PubMed ID: 23241074
    [Abstract] [Full Text] [Related]

  • 31. Effect of deferasirox on iron overload in patients with transfusion-dependent haemoglobinopathies.
    Fragomeno C, Roccabruna E, D'Ascola DG.
    Blood Cells Mol Dis; 2015 Dec 15; 55(4):382-6. PubMed ID: 26460263
    [Abstract] [Full Text] [Related]

  • 32. Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): a status quo.
    Taher AT, Musallam KM, Viprakasit V, Porter JB, Cappellini MD.
    Blood Cells Mol Dis; 2014 Dec 15; 52(2-3):88-90. PubMed ID: 24041597
    [No Abstract] [Full Text] [Related]

  • 33. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
    Fischer R, Piga A, Harmatz P, Nielsen P.
    Ann N Y Acad Sci; 2005 Dec 15; 1054():350-7. PubMed ID: 16339683
    [Abstract] [Full Text] [Related]

  • 34. Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study.
    Taher AT, Cappellini MD, Aydinok Y, Porter JB, Karakas Z, Viprakasit V, Siritanaratkul N, Kattamis A, Wang C, Zhu Z, Joaquin V, Uwamahoro MJ, Lai YR.
    Blood Cells Mol Dis; 2016 Mar 15; 57():23-9. PubMed ID: 26852651
    [Abstract] [Full Text] [Related]

  • 35. Objectives and mechanism of iron chelation therapy.
    Hershko C, Link G, Konijn AM, Cabantchik ZI.
    Ann N Y Acad Sci; 2005 Mar 15; 1054():124-35. PubMed ID: 16339658
    [Abstract] [Full Text] [Related]

  • 36. Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study).
    Ho PJ, Tay L, Teo J, Marlton P, Grigg A, St Pierre T, Brown G, Badcock CA, Traficante R, Gervasio OL, Bowden DK.
    Eur J Haematol; 2017 Feb 15; 98(2):97-105. PubMed ID: 27537786
    [Abstract] [Full Text] [Related]

  • 37. Deferasirox effect on renal haemodynamic parameters in patients with transfusion-dependent β thalassaemia.
    Piga A, Fracchia S, Lai ME, Cappellini MD, Hirschberg R, Habr D, Wegener A, Bouillaud E, Forni GL.
    Br J Haematol; 2015 Mar 15; 168(6):882-90. PubMed ID: 25402221
    [Abstract] [Full Text] [Related]

  • 38. Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload.
    Chen CH, Shu KH, Yang Y.
    Hematology; 2015 Jun 15; 20(5):304-10. PubMed ID: 25200910
    [Abstract] [Full Text] [Related]

  • 39. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
    Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, Files B, Hassell K, Kelly P, Wilson F, Bernaudin F, Forni GL, Okpala I, Ressayre-Djaffer C, Alberti D, Holland J, Marks P, Fung E, Fischer R, Mueller BU, Coates T, Deferasirox in Sickle Cell Investigators.
    Br J Haematol; 2007 Feb 15; 136(3):501-8. PubMed ID: 17233848
    [Abstract] [Full Text] [Related]

  • 40. Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state.
    Waldmeier F, Bruin GJ, Glaenzel U, Hazell K, Sechaud R, Warrington S, Porter JB.
    Drug Metab Dispos; 2010 May 15; 38(5):808-16. PubMed ID: 20097723
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.